ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

HCFA Sees Applications For DRGs And Research

September 27, 1985

Misconduct Finding Is ‘Rare,’ OSI official Tells NCAB

June 14, 1991

In Brief: Donaldson, Wilson Lead ASTRO; Thomas To Hear Arguments In Cigarette Case; Doll, Peto Honored

November 8, 1991

Totality Of Evidence Causes Concern About New Findings.

December 7, 2007

ESAs Increase Risk of Death by 11 Percent, Blood Clots by 59 Percent, Meta-Analysis Finds; Study To Be Updated At ASCO.

June 1, 2007

Concepts Approved For Developmental Therapeutics Program

June 19, 1987